Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression

Molecular Psychiatry

Volumn 21, Issue 10, 2016, Pages 1358-1365

  Felger, J C ^a,b   Li, Z ^a,b,c   Haroon, E ^a   Woolwine, B J ^a   Jung, M Y ^a   Hu, X ^c   Miller, A H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHENZHEN UNIVERSITY   (China)

^c Emory University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; DOPAMINE;

ADULT; AGED; ANHEDONIA; ARTICLE; BOLD SIGNAL; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DORSAL STRIATUM; FEMALE; FUNCTIONAL CONNECTIVITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INFLAMMATION; LOCOMOTION; MALE; MOTIVATION; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RESTING STATE NETWORK; SUPPLEMENTARY MOTOR AREA; VENTRAL STRIATUM; VENTROMEDIAL PREFRONTAL CORTEX; BRAIN; BRAIN MAPPING; COMPLICATION; IMMUNOLOGY; MAJOR DEPRESSION; METABOLISM; MIDDLE AGED; NERVE TRACT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PSYCHOLOGY; REWARD;

ADULT; ANHEDONIA; BRAIN; BRAIN MAPPING; C-REACTIVE PROTEIN; CEREBRAL CORTEX; CORPUS STRIATUM; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DOPAMINE; FEMALE; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOTIVATION; NEURAL PATHWAYS; REWARD;

EID: 84946781649     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.168     Document Type: Article

References (73)

1. Treadway MT, Pizzagalli DA. Imaging the pathophysiology of major depressive disorder - from localist models to circuit-based analysis. Biol Mood Anxiety Disord 2014; 4: 5.
2. Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA. Large-scale network dysfunction in major depressive disorder: a meta-analysis of resting-state functional connectivity. JAMA Psychiatry 2015; 72: 603-611.
3. Furman DJ, Hamilton JP, Gotlib IH. Frontostriatal functional connectivity in major depressive disorder. Biol Mood Anxiety Disord 2011; 1: 11.
4. Hamilton JP, Chen G, Thomason ME, Schwartz ME, Gotlib IH. Investigating neural primacy in Major Depressive Disorder: multivariate Granger causality analysis of resting-state fMRI time-series data. Mol Psychiatry 2011; 16: 763-772.
5. Vrieze E, Demyttenaere K, Bruffaerts R, Hermans D, Pizzagalli DA, Sienaert P et al. Dimensions in major depressive disorder and their relevance for treatment outcome. J Affect Disord 2014; 155: 35-41.
6. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 2010; 68: 748-754.
7. Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry 2008; 63: 1022-1029.
8. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009; 66: 407-414.
9. Harrison NA, Cercignani M, Voon V, Critchley HD. Effects of inflammation on hippocampus and substantia nigra responses to novelty in healthy human participants. Neuropsychopharmacology 2015; 40: 831-838.
10. Capuron L, Pagnoni G, Drake DF, Woolwine BJ, Spivey JR, Crowe RJ et al. Dopa-minergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry 2012; 69: 1044-1053.
11. Felger JC, Hernandez CR, Miller AH. Levodopa reverses cytokine-induced reductions in striatal dopamine release. Int J Neuropsychopharmacol 2015; 18; http://dx.doi.org/ 10.1093/ijnp/pyu084; advance online publication, 31 January 2015.
12. Felger JC, Mun J, Kimmel HL, Nye JA, Drake DF, Hernandez CR et al. Chronic interferon-alpha decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates. Neuropsychopharmacology 2013; 38: 2179-2187.
13. Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Curr Top Behav Neurosci 2013; 14: 135-151.
14. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
15. Pizzagalli DA. Depression, stress, and anhedonia: toward a synthesis and integrated model. Annu Rev Clin Psychol 2014; 10: 393-423.
16. Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev 2011; 35: 537-555.
17. Di Martino A, Scheres A, Margulies DS, Kelly AM, Uddin LQ, Shehzad Z et al. Functional connectivity of human striatum: a resting state FMRI study. Cereb Cortex 2008; 18: 2735-2747.
18. Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology 2010; 35: 4-26.
19. Kelly C, de Zubicaray G, Di Martino A, Copland DA, Reiss PT, Klein DF et al. L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study. J Neurosci 2009; 29: 7364-7378.
20. Kwak Y, Peltier S, Bohnen NI, Muller ML, Dayalu P, Seidler RD. Altered resting state cortico-striatal connectivity in mild to moderate stage Parkinson's disease. Front Syst Neurosci 2010; 4: 143.
21. Konova AB, Moeller SJ, Tomasi D, Volkow ND, Goldstein RZ. Effects of methyl-phenidate on resting-state functional connectivity of the mesocorticolimbic dopamine pathways in cocaine addiction. JAMA Psychiatry 2013; 70: 857-868.
22. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988; 45: 742-747.
23. Mugler JP 3rd, Brookeman JR. Three-dimensional magnetization-prepared rapid gradient-echo imaging (3D MP RAGE). Magn Reson Med 1990; 15: 152-157.
24. Heberlein KA, Hu X. Simultaneous acquisition of gradient-echo and asymmetric spin-echo for single-shot z-shim: Z-SAGA. Magn Reson Med 2004; 51: 212-216.
25. Li Z, Moore AB, Tyner C, Hu X. Asymmetric connectivity reduction and its relationship to "HAROLD" in aging brain. Brain Res 2009; 1295: 149-158.
26. Li Z, Santhanam P, Coles CD, Lynch ME, Hamann S, Peltier S et al. Increased "default mode" activity in adolescents prenatally exposed to cocaine. Hum Brain Mapp 2011; 32: 759-770.
27. Saad ZS, Glen DR, Chen G, Beauchamp MS, Desai R, Cox RW. A new method for improving functional-to-structural MRI alignment using local Pearson correlation. Neuroimage 2009; 44: 839-848.
28. Oathes DJ, Patenaude B, Schatzberg AF, Etkin A. Neurobiological signatures of anxiety and depression in resting-state functional magnetic resonance imaging. Biol Psychiatry 2015; 77: 385-393.
29. Wacker J, Dillon DG, Pizzagalli DA. The role of the nucleus accumbens and rostral anterior cingulate cortex in anhedonia: integration of resting EEG, fMRI, and volumetric techniques. Neuroimage 2009; 46: 327-337.
30. Postuma RB, Dagher A. Basal ganglia functional connectivity based on a meta-analysis of 126 positron emission tomography and functional magnetic resonance imaging publications. Cereb Cortex 2006; 16: 1508-1521.
31. Capuron L, Pagnoni G, Demetrashvili MF, Lawson DH, Fornwalt FB, Woolwine B et al. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 2007; 32: 2384-2392.
32. Haroon E, Woolwine BJ, Chen X, Pace TW, Parekh S, Spivey JR et al. IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology 2014; 39: 1777-1785.
33. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
34. Diekhof EK, Kaps L, Falkai P, Gruber O. The role of the human ventral striatum and the medial orbitofrontal cortex in the representation of reward magnitude - an activation likelihood estimation meta-analysis of neuroimaging studies of passive reward expectancy and outcome processing. Neuropsychologia 2012; 50: 1252-1266.
35. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
36. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 1995; 167: 99-103.
37. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996; 26: 477-486.
38. Ameli R, Luckenbaugh DA, Gould NF, Holmes MK, Lally N, Ballard ED et al. SHAPS-C: the Snaith-Hamilton pleasure scale modified for clinician administration. PeerJ 2014; 2: e429.
39. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. Oxford University Press: New York, USA, 1991.
40. Aparicio P, Diedrichsen J, Ivry RB. Effects of focal basal ganglia lesions on timing and force control. Brain Cogn 2005; 58: 62-74.
41. Shindo A, Terada S, Sato S, Ikeda C, Nagao S, Oshima E et al. Trail making test part a and brain perfusion imaging in mild Alzheimer's disease. Dement Geriatr Cogn Dis Extra 2013; 3: 202-211.
42. Marvel CL, Paradiso S. Cognitive and neurological impairment in mood disorders. Psychiatr Clin North Am 2004; 27: 19-36, vii-viii.
43. Backman L, Ginovart N, Dixon RA, Wahlin TB, Wahlin A, Halldin C et al. Age-related cognitive deficits mediated by changes in the striatal dopamine system. Am J Psychiatry 2000; 157: 635-637.
44. Demakis GJ. Frontal lobe damage and tests of executive processing: a meta-analysis of the category test, stroop test, and trail-making test. J Clin Exp Neuropsychol 2004; 26: 441-450.
45. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009; 71: 171-186.
46. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457.
47. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70: 31-41.
48. Moieni M, Irwin MR, Jevtic I, Olmstead R, Breen EC, Eisenberger NI. Sex differences in depressive and socioemotional responses to an inflammatory challenge: implications for sex differences in depression. Neuropsychopharmacology 2015; 40: 1709-1716.
49. Inagaki TK, Muscatell KA, Irwin MR, Moieni M, Dutcher JM, Jevtic I et al. The role of the ventral striatum in inflammatory-induced approach toward support figures. Brain Behav Immun 2015; 44: 247-252.
50. Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry 2009; 65: 296-303.
51. Torres MA, Pace TW, Liu T, Felger JC, Mister D, Doho GH et al. Predictors of depression in breast cancer patients treated with radiation: role of prior chemotherapy and nuclear factor kappa B. Cancer 2013; 119: 1951-1959.
52. Haroon E, Felger JC, Woolwine BJ, Chen X, Parekh S, Spivey JR et al. Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: Preliminary findings. Brain Behav Immun 2014; 46: 17-22.
53. Timpson NJ, Nordestgaard BG, Harbord RM, Zacho J, Frayling TM, Tybjaerg-Hansen A et al. C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian randomization. Int J Obes (Lond) 2011; 35: 300-308.
54. Rawson ES, Freedson PS, Osganian SK, Matthews CE, Reed G, Ockene IS. Body mass index, but not physical activity, is associated with C-reactive protein. Med Sci Sports Exerc 2003; 35: 1160-1166.
55. Eisenberger NI, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences. Neuroimage 2009; 47: 881-890.
56. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986; 51: 1173-1182.
57. Sobel ME, Becker MP. Asymptotic confidence intervals for indirect effects in structural equation model. In: Sociological Methodology. American Sociological Association: Washington, DC, USA, 1982, pp 290-312.
58. Fritz MS, Mackinnon DP. Required sample size to detect the mediated effect. Psychol Sci 2007; 18: 233-239.
59. Barnes KA, Cohen AL, Power JD, Nelson SM, Dosenbach YB, Miezin FM et al. Identifying basal ganglia divisions in individuals using resting-state functional connectivity MRI. Front Syst Neurosci 2010; 4: 18.
60. Downar J, Geraci J, Salomons TV, Dunlop K, Wheeler S, McAndrews MP et al. Anhedonia and reward-circuit connectivity distinguish nonresponders from responders to dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. Biol Psychiatry 2014; 76: 176-185.
61. Diekhof EK, Falkai P, Gruber O. Functional neuroimaging of reward processing and decision-making: a review of aberrant motivational and affective processing in addiction and mood disorders. Brain Res Rev 2008; 59: 164-184.
62. Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol 2012; 33: 315-327.
63. Felger JC, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM et al. Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol Psychiatry 2007; 62: 1324-1333.
64. Felger JC, Mun J, Kimmel H, Nye JA, Drake DF, Hernandez CR et al. Chronic interferon-alpha decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in non-human primates. Neuropsychopharmacology 2013; 38: 2179-2187.
65. Nunes EJ, Randall PA, Estrada A, Epling B, Hart EE, Lee CA et al. Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task. Psychopharmacology (Berl) 2014; 231: 727-736.
66. Vichaya EG, Hunt SC, Dantzer R. Lipopolysaccharide reduces incentive motivation while boosting preference for high reward in mice. Neuropsychopharmacology 2014; 39: 2884-2890.
67. Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci 2013; 14: 609-625.
68. Sainz J, Mata I, Barrera J, Perez-Iglesias R, Varela I, Arranz MJ et al. Inflammatory and immune response genes have significantly altered expression in schizophrenia. Mol Psychiatry 2013; 18: 1056-1057.
69. Meyer U, Schwarz MJ, Muller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther 2011; 132: 96-110.
70. Michopoulos V, Rothbaum AO, Corwin E, Bradley B, Ressler KJ, Jovanovic T. Psy-chophysiology and posttraumatic stress disorder symptom profile in pregnant African-American women with trauma exposure. Arch Womens Ment Health 2014; 18: 639-648.
71. Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsycho-pharmacol Biol Psychiatry 2008; 32: 445-450.
72. Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 2013; 38: 377-385.
73. Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R et al. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry; advance online publication, 24 March 2015; doi: 10.1038/mp.2015.22 [e-pub ahead of print].